The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE OR NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on that assumption, some 20 institutions representing different sectors of the health care system launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across multiple stakeholders, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.
PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

• **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers about how the field can make the health system more effective and efficient by targeting treatments to only those patients who will benefit.

• **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages regulators and other policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.

• **Evidence Development:** To encourage the swifter adoption of personalized medicine by health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- **PMC’s Public Policy Committee** helps shape emerging legislative, regulatory and reimbursement policies in the public sector.
- **PMC’s Patient Advocacy Organization Working Group** assesses the extent to which emerging policy developments will inhibit or encourage personalized, patient-centered health care.
- **PMC’s Pharma and Diagnostics Working Group** assesses the extent to which emerging policy developments will inhibit or encourage the development of personalized medicine products and services.
- **PMC’s Science Policy Committee** helps inform the medical practices of health care providers and the reimbursement policies of commercial payers.
- **PMC’s Health Care Working Group** develops best practices for health care providers delivering personalized medicine.

MEMBER BENEFITS

**CONTACT**

2,000+ leaders in personalized medicine via PMC’s member database

**INTERACT WITH**

200+ thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

**SAVE**

40% on registration for the Annual Personalized Medicine Conference
PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES
AlphaGenomix Laboratories
Laboratory Corporation of America (LabCorp)
Natera
Quest Diagnostics

DIAGNOSTIC COMPANIES
Agenda NV
Alacris Theranostics GmbH
Almac Diagnostics
Asuragen, Inc.
Caprion Proteomics
CareDx, Inc.
Circulogene
Cofactor Genomics
Dialectics
Foundation Medicine, Inc.
GeneCentric Diagnostics
Genomic Health, Inc.
Guardant Health
Inivata
MolecularMD
NanoString Technologies
QIAGEN, Inc.
Roche Diagnostics Corporation
Siemens Healthcare Diagnostics, Inc.
Somalogic, Inc.
Veracyte

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
AveXis
Freenome
Immatics US
Loxo Oncology
NeoN Therapeutics
Regeneron Genetics Center
Relay Therapeutics
Tango Therapeutics
Unum Therapeutics
WuXi NextCode

HEALTH INSURANCE COMPANIES
Harvard Pilgrim

INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom
PhRMA

IT/INFORMATICS COMPANIES
2bPrecise
Change Healthcare
Concert Genetics
Cota Healthcare
DNAneXus
Flatiron Health
GNS Healthcare
M2Gen
Medidata
Progknovse Inc.
Seven Bridges
Syapse
XiFIN, Inc.

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
Amgen, Inc.
Astellas Pharma Global Development
AstraZeneca Pharmaceuticals
Bausch Health Companies
Boehringer-Ingelheim
Bristol-Myers Squibb
Celgene
Eli Lilly and Company
Genentech, Inc.
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

NUTRITION, HEALTH & WELLNESS COMPANIES
International Vitamin Corporation

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
Alliance for Aging Research
Alzheimer’s Foundation of America
Asian & Pacific Islander American Health Forum
Bonnie J. Addario Lung Cancer Foundation
Bulgarian Association for Personalized Medicine
Clearity Foundation
Colorectal Cancer Alliance
Emily’s Entourage
Fight Colorectal Cancer
Food Allergy Research & Education
Friends of Cancer Research
Global Liver Institute
HealthyWomen
International Cancer Advocacy Network ("ICAN")
Lung Cancer Alliance
LUNGevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Blood Clot Alliance
National Health Council
National Patient Advocate Foundation
OpenOme
Team Trevor
THRVORS

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.
PERSONALIZED MEDICINE SERVICE PROVIDERS
23andMe
Genome Medical Intervention Insights
Michael J. Bauer, M.D., & Associates, Inc.
MolecularHealth
N-of-One, Inc.
Panaceutics
Sema4
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS
American Association for Cancer Research (AACR)
American Medical Association (AMA)
Association for Molecular Pathology (AMP)
Baylor Health Care System Precision Medicine Institute
Brigham and Women’s Hospital, Genomes2People Research Program
Brown University
Business Finland
Cambridge Cancer Genomics
Cancer Treatment Centers of America
Center for Medical Technology Policy
The Christ Hospital
College of American Pathologists
Colorado Center for Personalized Medicine
Coriell Institute for Medical Research
CREATE Health Translational Cancer Centre, Lund University
Duke Center for Research on Personalized Health Care
Essentia Institute of Rural Health
European Infrastructure for Translational Medicine
Geisinger
Genome British Columbia
Genome Canada
Harvard Business School Helmholtz Zentrum München
Hospital Albert Einstein
Inova Health System
Instituto de Salud Carlos III
Intermountain Healthcare
The Jackson Laboratory
Johns Hopkins Individualized Health
King Faisal Specialist Hospital and Research Centre
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
Mission Health, Fullerton Genetics Center
MIT Center for Precision Cancer Medicine
Moffitt Cancer Center
National Pharmaceutical Council
Nicklaus Children’s Hospital
North Carolina Biotechnology Center
NorthShore University HealthSystem
Ontario Genomics Institute
Partners HealthCare Personalized Medicine Precision Health Initiative at Cedars-Sinai
Precision Medicine Alliance, LLC
Qatar Biobank
Quebec Network for Personalized Health Care
Rutgers Cancer Institute of New Jersey
Sanford Imagenetics, Sanford Health
Stanford University School of Medicine
Swedish Cancer Institute
Thomas Jefferson University
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of Arizona Health Sciences
University of California, San Francisco (UCSF)
University of Pennsylvania Health System
University of Rochester
University of South Florida Marsawi College of Medicine
Vanderbilt University Medical Center
Wake Forest Baptist Medical Center
West Cancer Center

RESEARCH TOOL COMPANIES
Illumina, Inc.
Thermo Fisher Scientific

STRATEGIC PARTNERS
ADVI
Arnold & Porter Kaye Scholer, LLP
Artisan Healthcare Consulting
Bioscience Valuation BSV GmbH
Blue Latitude Health
Boston Healthcare Associates
Bradford Power
Bruce Quinn Associates
Cambridge Healthtech Institute
Center for Individual Opportunity
Ceres Health Research ConText
ConvergeHEALTH by Deloitte
CRD Associates, LLC
Credit Suisse
Defined Health
Dr. Nai Chi Chan
EdgeTech Law, LLP
EY Parthenon
Foley & Lardner, LLP
Foley Hoag, LLP

As of February 2019
Visit [pmc.portal.membersuite.com](pmc.portal.membersuite.com) to join the Coalition.

For more information, contact Kayla Smith, Director, Membership & Development, at ksmith@personalizedmedicinecoalition.org or 202-589-0070.

### DUES STRUCTURE

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large Public Corporation</td>
<td>$29,000</td>
</tr>
<tr>
<td>Small Public Corporation</td>
<td>$14,500</td>
</tr>
<tr>
<td>Trade Association (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &gt;50 FTEs</td>
<td>$5,775</td>
</tr>
<tr>
<td>Professional Society</td>
<td>$5,775</td>
</tr>
<tr>
<td>Private Corporation &lt;50 FTEs</td>
<td>$3,500</td>
</tr>
<tr>
<td>Strategic Partner</td>
<td>$2,900</td>
</tr>
<tr>
<td>Research, Education &amp; Clinical Care Institutions</td>
<td>$2,900</td>
</tr>
<tr>
<td>Sole Proprietor</td>
<td>$1,150</td>
</tr>
<tr>
<td>Patient Advocacy Group</td>
<td>$500</td>
</tr>
</tbody>
</table>
STAFF

Edward Abrahams, Ph.D.
President

Cynthia A. Bens
Senior Vice President, Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President, Science Policy

Faswilla Sampson, M.S.
Vice President, Operations

Christopher J. Wells, M.P.A.
Vice President, Public Affairs

Kayla Smith
Director, Membership & Development

David L. Davenport
Manager, Public Policy; Secretary to the Board

Lindsay Stephens
Senior Operations Coordinator

BOARD OF DIRECTORS

Stephen L. Eck, M.D., Ph.D.
Board Chair
Immatics US

Jay G. Wohlgemuth, M.D.
Board Vice Chair
Quest Diagnostics

Peter Maag, Ph.D.
Board Treasurer
CareDx

Kimberly J. Popovits
Board Secretary
Genomic Health

Bonnie J. Addario
Bonnie J. Addario Lung Cancer Foundation

Steven D. Averbuch, M.D.
Bristol-Myers Squibb (retired)

Randy Burkholder
PhRMA

William S. Dalton, Ph.D., M.D.
M2Gen

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Anne-Marie Martin, Ph.D.
Novartis

Susan McClure
Genome magazine

Howard L. McLeod, Pharm.D.
Moffitt Cancer Center

J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Michael Pellini, M.D.
Section 32

Hakan Sakul, Ph.D.
Pfizer, Inc.

Michael S. Sherman, M.D., M.B.A., M.S.
Harvard Pilgrim Health Care

Sean Tunis, M.D.
Center for Medical Technology Policy

Werner Verbiest
Johnson & Johnson